What You Ought to Know:
–Flatiron Health, a number one healthtech firm devoted to bettering most cancers care and advancing analysis utilizing real-world information, in the present day introduced the launch of six new hematology Panoramic datasets, representing one other essential second of scientific innovation that foundationally redefines the corporate’s real-world proof choices in blood cancers.
– Flatiron’s Panoramic information unlocks the corporate’s total affected person community, leveraging breakthrough AI and huge language mannequin capabilities alongside their in depth database to extract and validate medical information at unprecedented scale.
Flatiron Well being expands hematology analysis capabilities by way of AI-powered real-world datasets
Flatiron Well being, an unbiased affiliate of the Roche Group, is advancing real-world oncology analysis with the discharge of its new hematology Panoramic datasets, encompassing greater than 505,000 affected person data throughout 5 B-cell lymphoma subtypes and a number of myeloma. The datasets are a part of a broader repository of over 5 million most cancers affected person data, representing 1.5 billion information factors that mirror actual medical observe throughout various care settings. Collectively, they goal to remodel how hematologic malignancies are studied, understood, and handled by enabling data-driven insights that mirror sufferers’ real-world experiences.
Developed below Flatiron’s validated information high quality framework, the Panoramic datasets mark a six-fold improve in cohort dimension in comparison with the corporate’s prior hematology collections. They seize in depth longitudinal particulars together with measurable residual illness (MRD) testing and CAR-T remedy utilization—two key indicators of latest hematology observe. This depth of medical data permits researchers to look at trendy remedy patterns, adherence, and outcomes with larger precision, supporting the event of personalised therapeutic methods and extra inclusive trial designs.
Chief Government Officer Nathan Hubbard described the datasets as a fruits of Flatiron’s decade-long effort to construct a worldwide oncology proof infrastructure. He famous that combining the corporate’s confirmed AI and machine studying capabilities with scientific rigor allows extra exact, individualized look after sufferers with blood cancers. The brand new datasets additionally enhance interoperability, permitting streamlined analyses throughout associated lymphoma varieties and longitudinal monitoring of illness transformation over time.
Flatiron’s hematology program helps detailed investigations into complicated subgroups comparable to high-grade B-cell lymphomas with MYC, BCL2, and BCL6 rearrangements or a number of myeloma instances with high-risk cytogenetics. The information additionally facilitate evaluation of real-world effectiveness, molecular response, and hostile occasions—dimensions that complement proof from conventional medical trials. By offering built-in perception into inpatient and outpatient care, infusion and oral regimens, and mobile therapies, the datasets create a panoramic view of the affected person journey that was beforehand fragmented.
With greater than 250 publications and 275 upcoming analysis displays throughout world conferences in 2025, Flatiron continues to form the proof requirements of digital oncology. Its participation at ISPOR Europe and ASH 2025 underscores a broader objective: to responsibly apply synthetic intelligence and real-world proof towards increasing scientific entry to uncommon illness populations, closing persistent information gaps, and accelerating the subsequent technology of hematology innovation.
